Pharma Firms Pledge $250 Billion to Expand U.S. Manufacturing

Pharmaceutical companies have pledged more than $250 billion to expand domestic manufacturing and research following threats from Donald Trump to impose tariffs on drug imports. The president has signaled potential tariffs of up to 200%, though a framework with the European Union suggests a 15% rate, provided companies utilize a grace period for domestic expansion.

Major brand-name firms led the commitments, with Johnson & Johnson investing $55 billion, AstraZeneca pledging $50 billion, and Eli Lilly and Company committing $27 billion to build four new plants. The Trump administration views these investments as a success of its strategy to strengthen national security and harden supply chains.

Generic drugmakers, which provide over 90% of U.S. prescriptions, have remained largely hesitant due to thin profit margins. Only Hikma Pharmaceuticals USA and Amphastar Pharmaceuticals announced recent investments. While the administration celebrates the move, analysts warn that domestic production is typically more expensive and may not lower consumer costs or reduce reliance on foreign ingredients.